Literature DB >> 15886499

The N- and L-type calcium channel blocker cilnidipine suppresses renal injury in dahl rats fed a high-sucrose diet, an experimental model of metabolic syndrome.

Tomoyuki Konda1, Azusa Enomoto, Junko Matsushita, Akira Takahara, Toshiki Moriyama.   

Abstract

BACKGROUND/AIMS: The L/N-type calcium channel blocker (CCB) cilnidipine has been demonstrated to suppress progressive renal disease in a variety of experimental models, but the characteristic effects of N-type calcium channel blocking action on renal injury have not been examined in detail. Therefore, we investigated the beneficial effects of cilnidipine on renal injury in Dahl salt-sensitive (Dahl S) rats fed a high-sucrose diet (HSD), which mimics metabolic syndrome, and compared them with the effects of an L-type CCB, amlodipine.
METHODS: Male Dahl S rats were divided into groups with similar blood pressure at 8 weeks of age and fed an HSD. They received vehicle, cilnidipine or amlodipine for 27 weeks. At 35 weeks of age, urine and blood samples were collected for physiological analysis, and the kidneys were removed for histopathological evaluation.
RESULTS: Cilnidipine reduced albuminuria, glomerular hypertrophy, glomerular expression of ICAM-1, ED-1-positive cell infiltration and interstitial fibrosis compared with vehicle-treated rats. In contrast, amlodipine had no effect on these parameters. Urinary norepinephrine excretion, renal expression of renin mRNA and renal tissue levels of angiotensin II were increased only in the amlodipine-treated group.
CONCLUSION: Cilnidipine provided superior protection against renal damage compared with amlodipine in Dahl S rats given an HSD. The different effects between these two drugs may be partly explained by their different actions on the renal sympathetic nerve activity and the renin-angiotensin system through the N-type calcium channel blocking action.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15886499     DOI: 10.1159/000085713

Source DB:  PubMed          Journal:  Nephron Physiol        ISSN: 1660-2137


  15 in total

1.  The N-type and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a high-salt diet.

Authors:  Shizuka Aritomi; Hajime Koganei; Hirotaka Wagatsuma; Akira Mitsui; Tetsuya Ogawa; Kosaku Nitta; Tomoyuki Konda
Journal:  Heart Vessels       Date:  2010-10-05       Impact factor: 2.037

2.  Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats.

Authors:  Shizuka Aritomi; Kazumi Niinuma; Tetsuya Ogawa; Tomoyuki Konda; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2012-08-17       Impact factor: 2.801

3.  Effect of cilnidipine on normal to marginally elevated urine albumin-creatinine ratio in asymptomatic non-diabetic hypertensive patients: an exponential decay curve analysis.

Authors:  Takaaki Nakatsu; Shinji Toyonaga; Keiichi Mashima; Yoko Yuki; Aya Nishitani; Hiroko Ogawa; Toru Miyoshi; Satoshi Hirohata; Reishi Izumi; Shozo Kusachi
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

4.  Cilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: possible involvement of N-type calcium channel in podocyte.

Authors:  Yu-Yan Fan; Masakazu Kohno; Daisuke Nakano; Hiroyuki Ohsaki; Hiroyuki Kobori; Diah Suwarni; Naro Ohashi; Hirofumi Hitomi; Katsuhiko Asanuma; Takahisa Noma; Yasuhiko Tomino; Toshiro Fujita; Akira Nishiyama
Journal:  J Hypertens       Date:  2010-05       Impact factor: 4.844

5.  Influence of T-calcium channel blocker treatment on deterioration of renal function in chronic kidney disease.

Authors:  Kiyotsugu Omae; Tetsuya Ogawa; Kosaku Nitta
Journal:  Heart Vessels       Date:  2009-07-22       Impact factor: 2.037

6.  L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease.

Authors:  Masanori Abe; Noriaki Maruyama; Hiroko Suzuki; Atsushi Inoshita; Yoshinori Yoshida; Kazuyoshi Okada; Masayoshi Soma
Journal:  Heart Vessels       Date:  2012-08-23       Impact factor: 2.037

7.  N-type calcium channel inhibition with cilnidipine elicits glomerular podocyte protection independent of sympathetic nerve inhibition.

Authors:  Bai Lei; Daisuke Nakano; Yoshihide Fujisawa; Ya Liu; Hirofumi Hitomi; Hiroyuki Kobori; Hirohito Mori; Tsutomu Masaki; Katsuhiko Asanuma; Yasuhiko Tomino; Akira Nishiyama
Journal:  J Pharmacol Sci       Date:  2012-07-21       Impact factor: 3.337

8.  Amlodipine Reduces Inflammation despite Promoting Albuminuria in the Streptozotocin-Induced Diabetic Rat.

Authors:  Elizabeth R Flynn; David C Marbury; R Taylor Sawyer; Jonathan Lee; Christine Teutsch; Katalin Kauser; Christine Maric-Bilkan
Journal:  Nephron Extra       Date:  2012-07-06

9.  Comparison of the cardioprotective and renoprotective effects of the L/N-type calcium channel blocker, cilnidipine, in adriamycin-treated spontaneously-hypertensive rats.

Authors:  Shizuka Aritomi; Eri Harada; Kazumi Sugino; Mai Nishimura; Tarou Nakamura; Akira Takahara
Journal:  Clin Exp Pharmacol Physiol       Date:  2015-04       Impact factor: 2.557

10.  Additive effects of cilnidipine, an L-/N-type calcium channel blocker, and an angiotensin II receptor blocker on reducing cardiorenal damage in Otsuka Long-Evans Tokushima Fatty rats with type 2 diabetes mellitus.

Authors:  Yutaka Mori; Shizuka Aritomi; Kazumi Niinuma; Tarou Nakamura; Kenichi Matsuura; Junichi Yokoyama; Kazunori Utsunomiya
Journal:  Drug Des Devel Ther       Date:  2014-06-17       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.